Medpace (MEDP)
(Delayed Data from NSDQ)
$319.56 USD
+5.34 (1.70%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $319.71 +0.15 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$319.56 USD
+5.34 (1.70%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $319.71 +0.15 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Zacks News
CVS Health (CVS) Q3 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Strength in all three operating segments drove CVS Health's (CVS) revenues in the third quarter of 2021.
Exact Sciences (EXAS) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business registered an improvement in revenues during the third quarter on strong contributions from Cologuard volume growth.
Myriad Genetics (MYGN) Q3 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment drove Q3 sales despite a challenging business environment.
Henry Schein (HSIC) Q3 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Strengthening demand in the global dental and medical markets drove Henry Schein's (HSIC) revenues in the third quarter.
Hologic (HOLX) Q4 Earnings Surpass Estimates, 2022 View Dull
by Zacks Equity Research
Impressive performance by the Breast Health and GYN Surgical segments drives Hologic's (HOLX) fiscal fourth-quarter revenues.
Bio-Rad (BIO) Q3 Earnings Surpass Estimates, 2021 View Raised
by Zacks Equity Research
Strength in the Life Science and Clinical Diagnostics segments drove Bio-Rad's (BIO) revenues in the third quarter.
Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RFG
Medpace (MEDP) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 20.56% and 1.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Medpace (MEDP) Q3 Earnings Expected to Decline
by Zacks Equity Research
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medpace (MEDP) Moves 3.3% Higher: Will This Strength Last?
by Zacks Equity Research
Medpace (MEDP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Medpace (MEDP) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Medpace (MEDP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Medpace (MEDP) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 8.16% and 2.62%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medpace (MEDP) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 15.84% and -1.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Medpace (MEDP): Can Its 3.5% Jump Turn into More Strength?
by Zacks Equity Research
Medpace (MEDP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Medpace (MEDP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc (TDOC) and Dexcom Offer New Solutions for Diabetes
by Zacks Equity Research
Teladoc (TDOC) and Dexcom jointly provide solutions for patients with Type 2 diabetes, a common lifestyle-induced malady.
Medpace (MEDP) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 4.63% and 2.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Momentum Stocks to Buy for August 28th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 28th.
Top Ranked Momentum Stocks to Buy for August 26th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 26th.
Top Ranked Momentum Stocks to Buy for August 24th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 24th.
Medpace (MEDP) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Top Ranked Momentum Stocks to Buy for August 20th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 20th.